Seoul Pharma Co., Ltd (KOSDAQ:018680)
South Korea · Delayed Price · Currency is KRW 1,977.00
-15.00 (-0.75%)
At close: Aug 24, 2026
Seoul Pharma Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 23,225 | 35,911 | 38,592 | 44,655 | 58,646 | 66,918 | |
Market Cap Growth | -40.27% | -6.95% | -13.58% | -23.86% | -12.36% | -28.31% |
Enterprise Value | 22,322 | 46,093 | 44,514 | 45,715 | 75,292 | 82,364 |
Last Close Price | 1992.00 | 3080.00 | 3310.00 | 3830.00 | 5030.00 | 7850.00 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 32.00 | 47.65 | 22.72 | 12.70 | 68.58 | - |
PS Ratio | 0.45 | 0.69 | 0.72 | 0.85 | 1.17 | 1.65 |
PB Ratio | 0.57 | 0.88 | 0.96 | 1.16 | 1.66 | 3.53 |
P/TBV Ratio | 0.58 | 0.89 | 0.98 | 1.18 | 1.70 | 3.70 |
P/FCF Ratio | 2.31 | 35.05 | - | 13.24 | - | - |
P/OCF Ratio | 2.12 | 19.04 | - | 8.48 | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.43 | 0.88 | 0.83 | 0.87 | 1.50 | 2.04 |
EV/EBITDA Ratio | 17.00 | 33.34 | 11.08 | 14.56 | 17.30 | - |
EV/EBIT Ratio | - | - | 29.14 | 37.70 | 43.30 | - |
EV/FCF Ratio | 2.22 | 44.99 | - | 13.56 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.42 | 0.42 | 0.40 | 0.28 | 0.42 | 1.55 |
Debt / EBITDA Ratio | 13.12 | 12.58 | 4.01 | 3.49 | 3.43 | - |
Debt / FCF Ratio | 1.72 | 16.98 | - | 3.25 | - | - |
Net Debt / Equity Ratio | -0.02 | 0.18 | 0.21 | 0.03 | 0.09 | 0.82 |
Net Debt / EBITDA Ratio | -0.69 | 5.38 | 2.14 | 0.41 | 0.74 | -4.89 |
Net Debt / FCF Ratio | -0.09 | 7.27 | -1.64 | 0.38 | -2.45 | -5.50 |
Asset Turnover | 0.72 | 0.73 | 0.79 | 0.83 | 0.80 | 0.64 |
Inventory Turnover | 1.73 | 1.75 | 1.81 | 2.10 | 2.29 | 2.15 |
Quick Ratio | 1.59 | 1.51 | 1.20 | 0.72 | 1.20 | 0.64 |
Current Ratio | 2.38 | 2.28 | 2.28 | 1.25 | 1.87 | 0.86 |
Return on Equity (ROE) | 1.80% | 1.86% | 4.32% | 9.51% | 3.15% | -40.53% |
Return on Assets (ROA) | -1.19% | -1.11% | 1.42% | 1.21% | 1.74% | -5.61% |
Return on Invested Capital (ROIC) | -3.05% | -2.63% | 3.33% | 2.69% | 4.75% | -15.14% |
Return on Capital Employed (ROCE) | -2.40% | -2.30% | 2.70% | 2.80% | 3.60% | -17.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.13% | 2.10% | 4.40% | 7.88% | 1.46% | -14.48% |
FCF Yield | 43.24% | 2.85% | -13.57% | 7.55% | -2.24% | -4.23% |
Buyback Yield / Dilution | - | - | - | -29.84% | -5.34% | -0.31% |